InsuLife is a Norwegian company aiming at developing and bringing the unparalleled investigational Levellor™ spray-based insulin to market. This includes the carrying out of any and all necessary product studies and authorization activities.
Levellor™ will represent an international innovation and paradigm shift. Insulin in spray form has the potential to fulfill a need for people with diabetes who want to avoid needles and to take insulin in the most practical way.
There is no transdermal insulin spray in the global pharmaceutical market today. InsuLife are developing a novel product with delivery of of insulin by spray-on-the-skin will be easy and efficacy is expected to be comparable to the traditional subcutaneous injections.
The Future of Insulin Delivery
Levellor aims to be the first transdermal spray-on Insulin. Sprayed directly onto the skin, Levellor eliminates the use of needles. The target of this breakthrough product:
Eliminates multiple injections per day
Room temperature stable, requiring no refrigeration
Potential for better patient compliance
Utilizes unmodified human insulin, a “commodity” drug product enabling cost competitiveness
|
|
|
|
|
11-50 employees
View all InsuLife employees
|
|
|
Pharmaceutical Manufacturing
|
|
|
Oslo, NO
|
|
|
None
|
The decision makers in InsuLife are Age Naerdal, Christian H Theiste, Henrik Bruun Andersen, etc. Click to Find InsuLife decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.